At a glance
| Chemical type | Small molecule; not a peptide |
|---|---|
| Target | NNMT enzyme |
| Other name | 5-amino-1-methylquinolinium |
| Evidence | Cells and diet-induced obese mice |
| Approval | No approved therapeutic use identified |
Overview
Also written 5A1MQ or 5-amino-1-methylquinolinium, this compound is included because it appears in peptide-oriented catalogs despite its different chemistry. The experimental target, NNMT, participates in nicotinamide methylation and links to cellular energy and methyl-donor metabolism. Original studies used cultured adipocytes and diet-induced obese mice, with later work examining liver and metabolic outcomes. These findings support target investigation. They do not establish that blocking NNMT is beneficial in every tissue or that self-administered oral or injectable preparations reproduce the exposure achieved in controlled animal experiments.
How it works
NNMT converts nicotinamide to 1-methylnicotinamide using S-adenosylmethionine as a methyl donor. Inhibiting it can change intracellular nicotinamide-related metabolites, NAD-associated pathways and methyl-donor availability. Experimental 5-amino-1MQ studies connect those changes to reduced lipogenesis and altered energy handling. NNMT has tissue-specific functions, so a proposed metabolic benefit cannot be reduced to the claim that raising NAD is automatically beneficial throughout the body.
Early metabolic experiments
The original inhibitor study found reduced lipogenesis in cultured adipocytes and lower body weight and adipose mass in obese mice. The authors linked effects to changes in metabolic regulators, but did not establish a human weight-management treatment.
Supporting sources [1]
Later obesity and liver findings
A 2024 mouse study reported improvements in glucose tolerance, insulin sensitivity and liver fat-related pathology, alongside pharmacokinetic and tissue-distribution work. These are preclinical outcomes and should not be described as demonstrated reversal of human MASH.
Supporting sources [2]
Why a target is not a treatment
A compound can inhibit the intended enzyme yet have inadequate exposure, off-target activity or an unfavorable safety margin in people. Dose-response and tissue-distribution data from mice do not supply a clinically validated human regimen.
Human uncertainty
The cited research does not establish adverse-event frequencies, reproductive safety, long-term toxicity or drug interactions in humans. Short animal studies with no obvious toxicity cannot answer those questions. Product identity and purity add separate uncertainties outside regulated development.
Why it is labeled nonpeptide
Its methylquinolinium scaffold is not an amino-acid chain. Keeping that distinction visible prevents readers from assuming it shares the pharmacology, manufacturing requirements or clinical evidence of approved peptide medicines merely because sellers group them together.
Supporting sources [1]
Common questions
Is 5-Amino-1MQ actually a peptide? No. It is a small-molecule NNMT inhibitor and is included here because it appears in the reference catalog.
Have its animal weight and liver findings been established in patients? The cited studies are preclinical. They do not establish a human clinical benefit, a safe treatment regimen or a replacement for approved obesity or liver-disease care.
Reading this profile
Jurisdiction: Research compound; no FDA-approved 5-Amino-1MQ medicine identified.. Molecular class: Nonpeptide methylquinolinium small-molecule NNMT inhibitor.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. ↗Original research · Checked 2026-10-27
- Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction ↗Original research · Checked 2026-10-27
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. ↗Original research · Checked 2026-10-27